ArticleNano research2024
Materials Advancements for the Safety and Patency of Implantable Cardiovascular Devices.
Article in Nano research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiovascular Nanomedicine: Breakthroughs in Therapy-Challenges in Safety and Cardiotoxic Risks: A Comprehensive Review of Inorganic Nanoparticles.Cardiovascular toxicology · 2026Review
- The Challenges of Vascular Implants: Regulatory Strategies and Biological Responses.Small science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Implantable cardiovascular devices have revolutionized the management of cardiovascular diseases, significantly enhancing patients' quality of life. With the increasing demand of cardiac implantable electronic devices, the imperative for novel device development is evident. This review article first elaborates the mechanisms underlying foreign body response and infection, elucidating the complex interplay between implanted constructs and host tissues. The discussion then focuses on current advancements in materials science and engineering aimed at mitigating these challenges. Material innovations, such as drug-eluting materials, surface modifications, and biomimetic materials, are explored as strategies to modulate these responses and to prevent fibrotic or thrombotic complications and infection. Finally, future directions in materials development for implantable cardiovascular devices are introduced. By addressing safety and patency concerns through innovative material strategies, this article aims to guide the research and development of advanced materials for both current and future cardiovascular implantable devices, ultimately improving patient outcomes and advancing cardiovascular disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.